Since the involvement of astrocyte and microglia activation in SMARD1 disease is not well understood, in recent years in vitro (patients’ derived cells) and in vivo (transgenic mouse) models have been used to study their functional or pathological role in different neurodegenerative disorders including ALS. Here, IGHMBP2 is linked to amyotrophic lateral sclerosis.